Cipla Ltd ( (IN:CIPLA) ) has shared an announcement.
Cipla Limited has issued a corrigendum to its earlier intimation regarding the transcript of its 90th Annual General Meeting, noting that inadvertent typographical errors were identified in the version filed on 3 July 2026. The company has submitted a corrected AGM transcript to the BSE, NSE and the Luxembourg Stock Exchange and requested that the updated document be taken on record.
The 90th AGM, held via video conferencing on 25 June 2026, was attended by Cipla’s chairman, senior board members, key executives and representatives of statutory, secretarial and cost auditors, as well as assurance providers for its integrated and sustainability reports. The clarification underscores Cipla’s emphasis on accurate disclosure and governance transparency for shareholders and market regulators, reinforcing confidence in its reporting practices.
More about Cipla Ltd
Cipla Limited is a leading Indian pharmaceutical company headquartered in Mumbai, focused on manufacturing and marketing generic medicines and specialty therapeutics for global markets. The company operates across multiple therapeutic areas and serves both domestic and international healthcare segments through a broad portfolio of products and formulations.
It maintains a significant presence in regulated and emerging markets, supplying prescription drugs, over-the-counter products and active pharmaceutical ingredients. Cipla’s long-established industry position is supported by its extensive R&D capabilities and compliance with international regulatory standards, underpinning its role as a major player in the global generics industry.
Average Trading Volume: 125,282
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1176.4B INR
For an in-depth examination of CIPLA stock, go to TipRanks’ Overview page.